Home » Omthera Pharmaceuticals Presents Data From Analysis of EVOLVE Trial Showing Epanova Lowers ApoC-III
Omthera Pharmaceuticals Presents Data From Analysis of EVOLVE Trial Showing Epanova Lowers ApoC-III
Omthera Pharmaceuticals presented data from the company’s Phase III EVOLVE (EpanoVa fOr Lowering Very High triglyceridEs) trial at the Scientific Sessions of the American Heart Association.
The Sacramento Bee
The Sacramento Bee
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct